sentiment. Check out our BCRX stock analysis, current BCRX quote, charts, and historical prices for Biocryst Pharma Inc stock. According to . Biocryst Pharmaceuticals Inc. Stock Price Forecast, "BCRX" Predictons for2021 © 2020 Cable News Network. The official website for BioCryst Pharmaceuticals is www.biocryst.com. Forecast Cash Runway: BCRX is forecast to have sufficient cash runway for 9 months based on free cash flow estimates, but has since raised additional capital. BCRX | Complete BioCryst Pharmaceuticals Inc. stock news by MarketWatch. Top authors: BCRX. 8 Wall Street analysts that have issued a 1 year BCRX price target, the average BCRX price target is $10.63, with the highest BCRX stock price forecast at $14.00 and the lowest BCRX stock price forecast at $7.00. BCRX Stock Analysis - [Full Report] Free Signup: Advanced stock screener. BioCryst Pharmaceuticals, Inc. designs and develops novel, oral and small-molecule medicines. BCRX, 120. Bcrx a good oportunity for short term!? Never miss a profitable trade. In the past three months, BioCryst Pharmaceuticals insiders have sold more of their company's stock than they have bought. According to 10 analysts, the average rating for BCRX stock is "Buy." The stock is rated as a Hold by 1 analyst(s), 8 recommend it as a Buy and no body called the BCRX stock Outperform. Bullish. If compared to the average trading volume of 6.89M shares, BCRX reached a trading volume of 36828873 in the most recent trading day, which is why market watchdogs consider the stock to be active. View today's stock price, news and analysis for BioCryst Pharmaceuticals Inc. (BCRX). NASDAQ:BCRX - BioCryst Pharmaceuticals Stock Price Target and Predictions. Explore more healthy companies in the Pharmaceuticals & Biotech industry. 8 of the analysts rate the stock … Find the latest Earnings Report Date for BioCryst Pharmaceuticals, Inc. Common Stock (BCRX) at Nasdaq.com. All times are ET. This puts Jon P. Stonehouse in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies. Find the latest Earnings Report Date for BioCryst Pharmaceuticals, Inc. Common Stock (BCRX) at Nasdaq.com. All rights reserved. BCRX … View BioCryst Pharmaceuticals' earnings history. Looking for new stock ideas? According to . BCRX Stock Analysis Overview What this means: Biocryst Pharma Inc (BCRX) gets an Overall Rank of 66, which is an above average rank under InvestorsObserver's stock ranking system. Most Recent Rating. Vote “Outperform” if you believe BCRX will outperform the S&P 500 over the long term. According to analysts' consensus price target of $10.71, BioCryst Pharmaceuticals has a forecasted downside of 0.6% from its current price of $10.78. BCRX stock forecast Our latest prediction for Biocryst Pharmaceuticals Inc.'s stock price was made on the Aug. 11, 2020 when the stock price was at 3.96$.. The company's average rating score is 2.70, and is based on 7 buy ratings, 3 hold ratings, and no sell ratings. From InvestorPlace; From the Web; BioCryst Pharma News: Why BCRX Stock Is Soaring Today. Over the past year the S&P 500 is higher by 15.01% while BCRX is higher by 179.05%. Twitter. BioCryst Pharmaceuticals Stock Forecast NASDAQ:BCRX Price Target and Analyst Ratings. Analyst recommendations provided by FactSet shows that the consensus forecast for BioCryst Pharmaceuticals Inc. (BCRX) is a “Buy”. According to present data Sports Venues of Florida's BTHR shares and potentially its market environment have been in bearish cycle last 12 months (if exists). Specifically, they have bought $0.00 in company stock and sold $194,985.00 in company stock. If you’re ready to start capitalizing on this massive boom, legendary crypto investor Matt McCall just released a new free report, “3 Cryptos to Beat Bitcoin.”, President, Chief Executive Officer & Director, Chief Financial Officer & Senior Vice President, Chief Medical Officer & Senior Vice President, Secretary, Chief Legal Officer & Senior VP, Chief Business Officer & Senior Vice President, Start Your Risk-Free Trial Subscription Here, Warren Buffett again encourages investors to bet on America, Biden team readies wider economic package after virus relief, Fraud overwhelms pandemic-related unemployment programs, The Latest: U.S. FDA approves J&J single-shot vaccine, In oil-rich Iraq, a few women buck norms, take rig site jobs, The Latest: Utah cancels vaccine dates for thousands, The Latest: At 100, Captain Tom Moore honored at funeral, Cronos Stock Pulls Back After Earnings, It Might Be Time To Buy Some, Guardion Health Sciences Stock Needs to Give Investors More Than Survival, Wait For a Better Price Before Placing a Bet On Churchill Downs, 3 Small Cap Dividend Stocks with Growth Prospects, It’s Okay to Take the Over on DraftKings Stock, 7 Undervalued Stocks That Deserve More Attention, 7 Semiconductor Stocks Set to Gain From the Chip Shortage, 7 Great Dividend Stocks to Buy For a Comfortable Retirement, 7 Penny Stocks That Don’t Care About Robinhood, 7 Hotel Stocks Just Waiting For the Vaccine, 7 Stocks to Watch When Student Debt Forgiveness Gets Passed, 7 Healthcare Stocks Delivering Innovation in 2021, 7 Lithium Stocks That Will Power the Electric Vehicle Boom, 7 Electric Vehicle (EV) Stocks That Have Real Juice, 7 Post-Inauguration Stocks to Buy For Under $20, BioCryst's Orladeyo Wins EU Positive Opinion For Hereditary Angioedema, BioCryst Receives Positive CHMP Opinion for ORLADEYO™ (berotralstat), an Oral, Once-daily Therapy to Prevent Attacks in Patients with Hereditary Angioedema, BioCryst Pharmaceuticals (BCRX) Q4 2020 Earnings Call Transcript, Why BioCryst Pharmaceuticals Stock Is Falling Today, BioCryst Pharmaceuticals (BCRX) Reports Q4 Loss, Misses Revenue Estimates, BioCryst Pharmaceuticals, Inc. to Host Earnings Call, BioCryst Reports Fourth Quarter and Full Year 2020 Financial Results and Upcoming Key Milestones. Detailed Estimate. BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) announced its quarterly earnings results on Wednesday, February, 24th. Export data to Excel for your own analysis. When the symbol you want to add appears, add it to My Quotes by selecting it and pressing Enter/Return. Want to see which stocks are moving? BioCryst Pharmaceuticals Inc. (BCRX) Analyst Forecasts. There are currently 3 hold ratings and 7 buy ratings for the stock… Do Not Sell My Information. The consensus price target of analysts on Wall Street is $11.67, which implies a decline of -1.19% to the stock’s current value. BioCryst climbs after FDA approval for Rapivab in infants, BioCryst Announces FDA Approval of Supplemental New Drug Application for RAPIVAB® Expanding Patient Population to Include Children Six Months and Older, BioCryst Pharmaceuticals Reaches Analyst Target Price, The GameStop frenzy convinced more people to search 'how to buy stocks' than last year's surge, view top-rated stocks among Wall Street analysts, Receive Analysts' Upgrades and Downgrades Daily. Learn everything you need to know about successful options trading with this three-part video course. BCRX stock forecast Our latest prediction for Biocryst Pharmaceuticals Inc.'s stock price was made on the Aug. 11, 2020 when the stock price was at 3.96$.. Shares of BCRX can be purchased through any online brokerage account. You can opt out at any time. Most stock quote data provided by BATS. BCRX: BioCryst Pharmaceuticals, Inc. BCRX stock was sold by a variety of institutional investors in the last quarter, including Ghost Tree Capital LLC, Credit Suisse AG, Victory Capital Management Inc., Barclays PLC, Pura Vida Investments LLC, SG Americas Securities LLC, Edge Wealth Management LLC, and Formidable Asset Management LLC. BCRX Stock Forecast - Is BCRX a buy or sell? 100% FREE. BCRX may start an uptrend. Never miss a profitable trade. Vote “Underperform” if you believe BCRX will underperform the S&P 500 over the long term. Our system considers the available information about the company and then compares it to all the other stocks we have data on to get a percentile-ranked value. BioCryst Pharmaceuticals has only been the subject of 3 research reports in the past 90 days. BioCryst Pharmaceuticals is headquartered at 4505 EMPEROR BOULEVARD SUITE 200, DURHAM NC, 27703. BioCryst Pharmaceuticals (BCRX) came out with a quarterly loss of $0.34 per share versus the Zacks Consensus Estimate of a loss of $0.25. 70. Post-Market 0.16 (1.36%) MarketBeat just released five new trading ideas, but BioCryst Pharmaceuticals wasn't one of them. BCRX is higher by $0.61 from the previous closing price of $7.65 on volume of 5,929,634 shares. Find market predictions, BCRX financials and market news. 9 analyst(s) have assigned their ratings of the stock’s forecast evaluation on a scale of 1.00-5.00 to indicate a strong buy to a strong sell recommendation. Wall Street Stock Market & Finance report, prediction for the future: You'll find the Sports Venues of Florida share forecasts, stock quote and buy / sell signals below. 2. View today's stock price, news and analysis for BioCryst Pharmaceuticals Inc. (BCRX). Date Range. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. 60-Month Beta: Coefficient that measures the volatility of a stock's returns relative to the market (S&P 500). BioCryst Pharmaceuticals trades on the NASDAQ under the ticker symbol "BCRX.". All Rights Reserved. BIOCRYST PHARMACEUTICALS INC (BCRX.MX) stock forecast and price target. This compares to loss of $0.02 per share a year ago. Biocryst Pharmaceuticals Inc. (BCRX) Stock Price has been Trending Strongly with an ADX reading of 48.22 as per the Weekly Chart. Date Rating Action Authority Current Price Target Price; 2021-01-22 : Sector Perform: Target Raised by: … A Warner Media Company. report type. BioCryst Pharmaceuticals does not have a long track record of dividend growth. According to the market data, Biocryst Pharmaceuticals Inc. (BCRX) stock price is $9.79 and the 52 weeks low is $1.6, which means the Biocryst Pharmaceuticals Inc. stock price is up 224.92% in the last 12 months. The price target was set to $7.00 → $9.00. investment rating. sector. BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Stock Forecast: Upsidde of 33.51% by 2021. Here is what top equities market gurus are saying about BioCryst Pharmaceuticals Inc. [BCRX]: Based … Get the latest BioCryst Pharmaceuticals, Inc. BCRX detailed stock quotes, stock data, Real-Time ECN, charts, stats and more. But they’d be setting their sights too low. Long term indicators fully support a continuation of the … Excited for Q4 earnings and more importantly Q1. Find real-time BXRX - Baudax Bio Inc stock quotes, company profile, news and forecasts from CNN Business. The company was founded in 1986 and is headquartered in Durham, NC. During the day the stock fluctuated 12.21% from a day low at $11.06 to a day high of $12.41. Company insiders that own BioCryst Pharmaceuticals stock include Alane P Barnes, Anthony Doyle, Jon P Stonehouse, Kenneth B Lee Jr, Megan Sniecinski, Steve Aselage and Thomas R Staab II. … The Barchart Technical Opinion rating is a 100% Buy and ranks in the Top 1% of all short term signal directions. Compare Top Brokerages Here. Dividend. 10 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for BioCryst Pharmaceuticals in the last year. Decreased. Target and Analyst Ratings; Price Target History; Upgrades and Downgrades; About; Consensus Rating: Buy; Consensus Price Target: $9.07; Forecasted Upside: 48.71 %; Number of Analysts: 10; Breakdown: 0 Sell Ratings; 3 Hold Ratings; 7 Buy Ratings; 0 Strong Buy Ratings $ 6.10 As of 12/4/2020 … View insider buying and selling activity for BioCryst Pharmaceuticals or view top insider-selling stocks. BCRX | Complete BioCryst Pharmaceuticals Inc. stock news by MarketWatch. View all of BCRX's competitors. Their average twelve-month price target is $10.71, predicting that the stock has a possible downside of 0.61%. Last 30 Days. By 4.47M Shares Last Quarter. BCRX Blogger Predictions > Hedge Fund Activity . Sign-up to receive the latest news and ratings for BCRX and its competitors with MarketBeat's FREE daily newsletter. Price/Sales: Latest closing price divided by the last 12 months of revenue/sales per share. Biocryst Pharmaceuticals (BCRX) stock price prediction is 15.246632 USD. Get the latest BioCryst Pharmaceuticals, Inc. BCRX detailed stock quotes, stock data, Real-Time ECN, charts, stats and more. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. BCRX Blogger Predictions > Hedge Fund Activity . Only 4.30% of the stock of BioCryst Pharmaceuticals is held by insiders. On the technical side, indicators suggest BCRX has a 50% Buy on average for the short term. The 12-month stock price forecast is 11.88, which is an increase of 6.17% from the latest price. In the meantime, none analyst(s) believe the stock as Underperform and none think it is a Sell. One share of BCRX stock can currently be purchased for approximately $10.78. sentiment. MarketBeat thinks these five stocks may be even better buys.View MarketBeat's top stock picks here. View which stocks are hot on social media with MarketBeat's trending stocks report. The biotechnology company reported ($0.34) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.25) by $0.09. 100% FREE. Get short term trading ideas from the MarketBeat Idea Engine. The … Because I’ve built a portfolio that pays us a 69% cash on cash return -- with no leverage, options, or gimmicks. Average Price Target : $11.44. Receive a free world-class investing education from MarketBeat. This suggests that the stock has a possible downside of 0.6%. View Baudax Bio, Inc. BXRX investment & stock information. View our earnings forecast for BioCryst Pharmaceuticals. BCRX, 240. As a result, BCRX is trading at a discount of 35.48% off the target high and -23.79% off the low. Should I buy or sell BCRX? Learn about financial terms, types of investments, trading strategies and more. What Kind Of Shareholders Hold The Majority In BioCryst Pharmaceuticals, Inc.'s (NASDAQ:BCRX) Shares? ), BioCryst Pharmaceuticals has received 408 “underperform” votes. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. According to analyst consensus estimates figures, the company’s yearly revenue forecast for 2021 is expected to hit $32.08 Million, or -34.3% down from figures reported last year. Wall Street analysts have given BioCryst Pharmaceuticals a "Buy" rating, but there may be better short-term opportunities in the market. The P/E ratio of BioCryst Pharmaceuticals is -14.18, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. To hit the forecast high, the stock’s price needs a +50.23% upsurge from its latest level, while the stock would need to tank -15.49% for it to hit the projected low. Get the latest Baudax Bio, Inc. BXRX detailed stock quotes, stock data, Real-Time ECN, charts, stats and more. Dividend Yield vs … View analysts' price targets for BioCryst Pharmaceuticals or view top-rated stocks among Wall Street analysts. Consensus. The biotechnology company earns $-108,900,000.00 in net income (profit) each year or ($0.94) on an earnings per share basis. You may vote once every thirty days. BCRX Stock Forecast - Is BCRX a buy or sell? BioCryst Pharmaceuticals has a P/B Ratio of 41.46. Find the latest analyst research for BioCryst Pharmaceuticals, Inc. Common Stock (BCRX) at Nasdaq.com. Currently there seems to be a trend where stocks in the … All rights reserved. Decreased. Long. Find out now with a free analysis on BioCryst Pharmaceuticals. Stock price today. bcrx stock forecast for the next 10 days by pretiming. Price Target Chicago Mercantile Association: Certain market data is the property of Chicago Mercantile Exchange Inc. and its licensors. For med term i recomand this stock entry point 8/9.50 price target 15+! … On the other hand, looking at the outlook for the BCRX stock, short term indicators assign the stock an average of 100% Buy, while medium term indicators assign it an average of 100% Buy. It is based on a 60-month historical regression of the return on the stock onto the return on the S&P 500. Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter. BCRX forecasts Videos only. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. Biocryst Pharmaceuticals Stock Forecast, BCRX stock price prediction. Standard & Poor's and S&P are registered trademarks of Standard & Poor's Financial Services LLC and Dow Jones is a registered trademark of Dow Jones Trademark Holdings LLC. BCRX stock price has been found in the range of $10.21 to $12.04. Find out now with a free analysis on BioCryst Pharmaceuticals. Top authors: BCRX. 0. Based on aggregate information from My MarketBeat watchlists, some companies that other BioCryst Pharmaceuticals investors own include Inovio Pharmaceuticals (INO), El Pollo Loco (LOCO), Advanced Micro Devices (AMD), Idera Pharmaceuticals (IDRA), OPKO Health (OPK), Dynavax Technologies (DVAX), La Jolla Pharmaceutical (LJPC), Novavax (NVAX), Sorrento Therapeutics (SRNE) and VBI Vaccines (VBIV). All content of the Dow Jones branded indices © S&P Dow Jones Indices LLC 2019 and/or its affiliates. Barchart Technical Opinion . Stock market forecast - Daily Investment position => Neutral - Bullish (It might be changed by the supply-demand strength.) Get the hottest … Factset: FactSet Research Systems Inc.2019. BioCryst stock forecast & analyst price target predictions based on 9 analysts offering 12-months price targets for BCRX in the last 3 months. See what's happening in the market right now with MarketBeat's real-time news feed. MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Biocryst Pharmaceuticals Inc. Stock Price Forecast, "BCRX" Predictons for2021 Find real-time BLRX - BioLine RX Ltd stock quotes, company profile, news and forecasts from CNN Business. Their forecasts range from $6.00 to $14.00. 9 analyst(s) have assigned their ratings of the stock’s forecast evaluation on a scale of 1.00-5.00 to indicate a strong buy to a strong sell recommendation. Find real-time BCRX - BioCryst Pharmaceuticals Inc stock quotes, company profile, news and forecasts from CNN Business. BCRX Sentiment 100% Sector Average 71%. Since then, BCRX shares have increased by 345.2% and is now trading at $11.53. BioCryst Pharmaceuticals employs 140 workers across the globe. Facebook. Jon P. Stonehouse has an approval rating of 40% among BioCryst Pharmaceuticals' employees. BioCryst Pharmaceuticals has received 434 “outperform” votes. BCRX: 11.81 (+6.49%) More news for this symbol. Identify stocks that meet your criteria using seven unique stock screeners. MarketBeat does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security. View institutional ownership trends for BioCryst Pharmaceuticals. 72.00% of the stock of BioCryst Pharmaceuticals is held by institutions. BioCryst Pharmaceuticals, Inc. (BCRX) estimates and forecasts The 12-month stock price forecast is 11.88, which is an increase of 6.17% from the latest price. BioCryst Pharmaceuticals' management team includes the following people: The cryptocurrency market is exploding in value right now… Bitcoin broke through $30,000…. Get daily stock ideas top-performing Wall Street analysts. By. BioCryst Pharmaceuticals, Inc. (BCRX) stock is higher by 7.97% while the S&P 500 has fallen -0.65% as of 1:16 PM on Friday, Dec 11. BioCryst Pharmaceuticals' stock is owned by many different retail and institutional investors. In the short term (2weeks), BCRX's stock price should underperform the market by -0.19%.During that period the price should oscillate between -10.74% and +13.37%. View BioCryst Pharmaceuticals, Inc. BCRX investment & stock information. 326 E 8th St #105, Sioux Falls, SD 57103 | [email protected] | (844) 978-6257 (Add your “underperform” vote.). The trading price of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) floating lower at last check on Monday, Jan 11, closing at $7.74, -3.26% lower than its previous close. 8 of the analysts rate the stock … © 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Dow Jones: The Dow Jones branded indices are proprietary to and are calculated, distributed and marketed by DJI Opco, a subsidiary of S&P Dow Jones Indices LLC and have been licensed for use to S&P Opco, LLC and CNN. Learn more. Over the past year the S&P 500 is higher by 15.01% while BCRX is higher by 179.05%. Its drug candidates include Berotralstat, BCX9930, BCX9250, RAPIVAB, ALPIVAB, RAPIACTA, PERAMIFLU, Galidesivir and Mundesine. BCRX stock forecast for the next 10 days by pretiming. BCRX forecasts Videos only. View which stocks have been most impacted by COVID-19. On January 22, 2021 "Royal Bank of Canada" gave "Sector Perform" rating for BCRX. Bullish. BioCryst Pharmaceuticals does not currently pay a dividend. To add symbols: Type a symbol or company name. BioCryst Pharmaceuticals' stock was trading at $2.59 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). IonutCiuchi. MarketBeat's community ratings are surveys of what our community members think about BioCryst Pharmaceuticals and other stocks. BCRX Stock Analysis Overview What this means: Biocryst Pharma Inc (BCRX) gets an Overall Rank of 66, which is an above average rank under InvestorsObserver's stock ranking system. (Add your “outperform” vote. BCRX stock was bought by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Voloridge Investment Management LLC, BlackRock Inc., North Star Investment Management Corp., Silverarc Capital Management LLC, Price T Rowe Associates Inc. MD, Los Angeles Capital Management LLC, and Golden Green Inc.. Company insiders that have bought BioCryst Pharmaceuticals stock in the last two years include Alane P Barnes, Anthony Doyle, Jon P Stonehouse, Kenneth B Lee Jr, Megan Sniecinski, and Steve Aselage. The 12-month stock price forecast is 11.88, which is an increase of 6.17% from the latest price. Since then, BCRX shares have increased by 316.2% and is now trading at $10.78. Disclaimer. View our full suite of financial calendars and market data tables, all for free. WhatsApp. In the short term (2weeks), BCRX's stock price should underperform the market by -0.19%.During that period the price should oscillate between -10.74% and +13.37%. BioCryst Pharmaceuticals has received a consensus rating of Buy. BioCryst Pharmaceuticals, Inc. (BCRX) estimates and forecasts Notifications > RSS.feed pretiming (Go to RSS.feed) > Pretiming analysis will be updated one by one at GMT 0:00 everyday > Please read a guide how to use pretiming analysis. Trend. 8 Wall Street analysts that have issued a 1 year BCRX price target, the average BCRX price target is $10.63, with the highest BCRX stock price forecast at $14.00 and the lowest BCRX stock price forecast at $7.00. BioCryst Pharmaceuticals (NASDAQ:BCRX) Price Target and Consensus Rating 10 Wall Street analysts have issued ratings and price targets for BioCryst Pharmaceuticals in the last 12 months. Limited Time Only. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. Long. The stock is rated as a Hold by 1 analyst(s), 8 recommend it as a Buy and no body called the BCRX stock Outperform. Limited Time Only. After a bit of correction and going down to sub $9 last … Learn more. BioCryst Pharmaceuticals Inc. (BCRX) Analyst Forecasts. All rights reserved. BIOCRYST PHARMACEUTICALS INC (BCRX.MX) stock forecast and price target. Given the current short-term trend, the stock is expected to rise 70.09% during the … Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Next Steps Explore more healthy companies in the Pharmaceuticals & Biotech industry. BioCryst Pharmaceuticals' mailing address is 4505 EMPEROR BOULEVARD SUITE 200, DURHAM NC, 27703. (Go to a guide) > If you can't find pretiming analysis of the latest date or not exist Please sign … According to 10 analysts, the average rating for BCRX stock is "Buy." 0. BioCryst Pharmaceuticals Inc (BCRX:DEU) forecasts: consensus recommendations, research reports, share price forecasts, dividends, and earning history and estimates.